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Chronic renal failure, but why?
A Case Report. 
Palak Patel, OMS-III†, Dr. Michael Rothberg, MD††
† Rowan University School of Osteopathic Medicine 
††Department of Internal Medicine, Ocean Medical Center, Brick, NJ
Renal failure, both acute and chronic, can present from many different etiologies 
and if diagnosed with diabetes mellitus, it is commonly assumed to be due to 
diabetic nephropathy. Monoclonal gammopathy of renal significance (MGRS) is 
a disorder that combines monoclonal gammopathy of undetermined significance 
with end stage renal disease. Monoclonal immunoglobulins are secreted by B or 
plasma cells leading to deposition in the kidney causing end organ damage. 
Several different subtypes fall under this category of renal diseases including, 
but not limited to, amyloidosis, C3 glomeruopathy, and light chain proximal 
tubulopathy, or better known as Fanconi syndrome1. Fanconi syndrome, which 
can be acquired or inherited, occurs due to toxicity of the proximal renal tubule 
in the kidney which leads to hypophosphatemia, hypokalemia, metabolic 
acidosis due to impaired bicarbonate absorption, impaired glucose and uric acid 
absorption, and proteinuria. 
84 year old Caucasian male presented to the emergency department with
complaints of shortness of breath and weakness. He had c/o decreased appetite
and urinary retention for a few days. He denied chest pain, hemoptysis, polyuria,
and hematuria. His past medical history includes chronic renal disease secondary
to type II diabetes mellitus (DM), perirenal lymphangiectasis, pulmonary
fibrosis, hypertension, atrial fibrillation, hyperlipidemia, and anemia of chronic
disease. He had a left radiocephalic AV fistula permacath placement 3 days prior
to admission for dialysis and has had a left hip replacement. He reports no
tobacco use, no alcohol use, no allergies, and no significant family history.
• Medications: insulin, doxazosin, carvedilol, sitagliptin, atorvastatin, epoetin
alfa, torsemide, hydralazine
* no recent heparin administration
• Initial vital signs: BP: 141/60, HR 56, RR:18, O2: 95%
• Positive exam signs: bilateral extremity swelling, generalized weakness,
decreased breath sounds bilaterally at both lung bases
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DIAGNOSTIC/TREATMENT MODALITIES
• Chest x-ray PA/Lateral 
• On admission: Left base opacification with patchy bilateral disease and 
pulmonary vascular congestion
• Post-pericardiocentesis: moderate CHF and cardiomegaly 
• Urinalysis = moderate hematuria, glucosuria, proteinuria
• Platelet transfusion and steroids for persistent thrombocytopenia 
• Heparin induced thrombocytopenia platelet factor-4 antibodies = not detected
• Echocardiogram = moderate to large pericardial effusion 
• Pericardiocentesis = 600 mL of straw-colored aspirated
• Serum protein electrophoresis (SPEP) = M-spike
• Immunofixation serum electrophoresis = IgG type kappa monoclonal protein
• Bone marrow biopsy = Monoclonal gammopathy of undetermined of significance 
(MGUS)
• Complement panel, ANA, c-ANCA and p-ANCA
• Renal Ultrasound = abnormal appearance of renal parenchyma with numerous 
cysts and septations; Indeterminate 4 mm right renal echogenic lesion
Lab (Normal Range) Day 0 Day 5 Day 16 Day 19
WBC (4.5-11 K/uL) 6.8 6.4 20.1 18.3
Neutrophil (50-70%) 81.7 72 92.5 90.2
CO2 (24-31 mmol/L) 17
Anion Gap (5-13) 16
BUN (5-25 mg/dL) 63 36 35 90
Uric acid (4.0-8.0 mg/dL) 2.8
Creatinine (0.44-1.0 mg/dL) 4.21 3.00 1.71 2.99
Hemoglobin (12-16 gm/dL) 10.1 9.8 10.4 8.9
Hematocrit (36-53%) 32.3% 30.1 30.6 27.0
Platelet Count* (140-450 K/uL) 157 33 89a 81
Albumin (3.5-5.0 mg/dL) 2.6 2.5 2.4
Cr-clearance (91-137 mL/min) 11 24 24 7
Protein (6.0-8.0 g/dL) 7.0 5.7 5.0
Glucose (70-99 mg/dl) 134 158 238 191
Potassium (3.5-5.2 mmol/L) 5.0 4.7 3.2 3.1
Phosphorus (2.5-4.6 mg/dL) 6.2 1.6 1.3 1.8
BNP (<100 pg/mL) 1772
SPEP Day 5 Day 12
Kappa QT (3.3-19.4) 197.75
Lambda QT (5.71-26.3) 86.40
Kappa/Lambda ratio (0.26-1.65) 2.29
Beta Protein (0.6-1.3) 1.64
Beta-2 Microglobulin (1.1-2.4 mg/L) 11.4
Complement Levels Day 14 Day 23
C3 (85-170 mg/dL) 62.6 46.4
C4 (16-40 mg/dL) 14.3 11.7
a. 1 day post-platelet transfusion – levels decreased from 176K to 89K
A combined team effort from general internal medicine, nephrology, 
hematology/oncology, cardiology, pulmonary, vascular, infectious 
disease, radiology, and pathology was made to investigate the patients’ 
present illness and provide a diagnosis that would be causing his many 
symptoms. Over the course of the patient’s one-month stay, a series of 
blood tests, imaging, and procedures were ordered to diagnose the 
etiology of his acute on chronic renal failure: 
1. ANA and ds DNA IgG to rule out lupus 
1. Normal level = 0.64 
2. Negative c-ANCA and p-ANCA  to rule out vasculitidies
3. Negative glomerular basement membrane IgG to rule out 
Goodpasture syndrome
4. Negative Cryo quant screen to rule out mixed cryoglobulinemia
5. Negative ASO titer
6. Negative hepatitis panel 
7. Significantly low C3 and mildly low C4 levels
• Possible C3 Glomerulopathy2 = monoclonal gammopathy-
associated proliferative glomerulonephritis
• Requires a kidney biopsy 
8. Pericardial effusion secondary to uremia from renal failure 
9. Anion gap metabolic acidosis secondary to uremia 
A bone marrow biopsy lead to the finding of monoclonal gammopathy
of undetermined significance (MGUS) with end-organ damage =
MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS)
1. Monoclonal spike on SPEP
2. Increased kappa Ig, lambda Ig, and  Kappa/Lambda ratio
3. Immunofixation electrophoresis = IgG monoclonal protein
4. Can cause proximal light chain tubulopathy (isolated proximal 
renal tubular acidosis) = FANCONI SYNDROME
• Immunoglobulin light chains can lead to proximal renal toxicity 
due to the inability of lysosomal proteases to break them 
down3. 
• Hypophosphotemia, hypouricemia, hypokalemia, metabolic 
acidosis, elevated kappa and lambda immunoglobulin chains
Though type II DM played a role in the development of this 
patient’s chronic kidney disease, MGRS is a significant causal factor 
of the progression to end stage renal disease. Currently, treatment 
with chemotherapy that targets plasma or B cells can be used for 
MGRS. Several case studies reported improvement or stabilization 
of renal function in those treated with chemotherapeutic agents vs. 
no therapy4,5.  Though renal transplantation can be done, recurrence 
post-transplantation is common6. The main goal in managing MGRS 
with Fanconi syndrome is slowing the progression of renal disease 
and preventing associated extra-renal complications7. 
